Trials / Active Not Recruiting
Active Not RecruitingNCT06679985
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Coherus Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main goals of this study are to evaluate the safety and efficacy of casdozokitug in combination with toripalimab plus bevacizumab and to define a recommended dose for casdozokitug in combination with toripalimab plus bevacizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Casdozokitug | Solution for infusion |
| DRUG | Toripalimab | Solution for infusion |
| DRUG | Bevacizumab | Solution for infusion |
Timeline
- Start date
- 2024-12-20
- Primary completion
- 2027-09-01
- Completion
- 2027-09-01
- First posted
- 2024-11-08
- Last updated
- 2026-04-13
Locations
44 sites across 6 countries: United States, Australia, Canada, Hong Kong, Singapore, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06679985. Inclusion in this directory is not an endorsement.